Long-term study of APG777 for atopic dermatitis in people already treated with it
Tests APG777 long term in adults with atopic dermatitis who finished an earlier APG777 study.
Plain-language title generated from the registry record
Registry title: A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Key facts
- Where
- Augsburg, Bad Bentheim, Berlin, Blankenfelde-Mahlow, Darmstadt, Dresden, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg, Kiel, München, Münster, and Tübingen, GermanySee the 14 sites
- Phase
- Phase 2
Where in Germany
- AugsburgAugsburg, GermanyTaking people
- Bad BentheimBad Bentheim, GermanyTaking people
- BerlinBerlin, GermanyTaking people
- Blankenfelde-MahlowBlankenfelde-Mahlow, GermanyTaking people
- DarmstadtDarmstadt, GermanyTaking people
- DresdenDresden, GermanyTaking people
- Frankfurt am MainFrankfurt am Main, GermanyTaking people
- Freiburg im BreisgauFreiburg im Breisgau, GermanyTaking people
- HamburgHamburg, GermanyTaking people
- HeidelbergHeidelberg, GermanyTaking people
- KielKiel, GermanyTaking people
- MünchenMünchen, GermanyTaking people
- MünsterMünster, GermanyTaking people
- TübingenTübingen, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Apogee Therapeutics, Inc.
- Trial code
- NCT07003425
- Record updated
- 3 November 2026
- Original description
This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948).Read full original descriptionShow less
A Long-term Extension Study to Evaluate the Safety and Efficacy of APG777 in Patients With Atopic Dermatitis Previously Treated With APG777
This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948).
The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period.
This study will be conducted in participants with atopic dermatitis (AD) who completed the Treatment Period in a prior APG777 study and who, in the opinion of the Investigator, would benefit from long-term treatment with APG777.
Inclusion: Participants who have completed the Treatment Period in a prior APG777 study and were, in the Investigator's opinion, compliant with the study protocol; Participants who, in the Investigator's opinion, would benefit from long-term treatment with APG777; Use the same non-prescription non-medicated emollient/moisturizer of their choice from the last day of the Parent Study and throughout the LTE study.
Exclusion: Participants who have developed an AE while participating in the Parent Study, which, in the opinion of the Investigator or of the Medical Monitor, could indicate that continued treatment with APG777 may present an unreasonable risk for the patient; Participants who terminated early from the Parent Study or permanently discontinued the study drug during the Parent Study; Use of any of the prohibited medications from Screening Visit (Visit 1) of the LTE study; Presence of dermatologic conditions and/or comorbidities that might confound the diagnosis of AD and/or interfere with study assessments; Note: Additional protocol defined Inclusion/Exclusion criteria may apply.